TTLL12 as A Potential Drug Target for Leukemia (G23170)

Target Name: TTLL12

NCBI ID: G23170

TTLL12

TTLL12 as A Potential Drug Target for Leukemia

TTLL12 (FLJ41795) is a protein that is expressed in various tissues and cells in the human body. It is a member of the T-cell leukemia family and is known for its role in the development and progression of various types of leukemia. TTLL12 has also been identified as a potential drug target (or biomarker) for the treatment of leukemia and other diseases.

TTLL12 is a transmembrane protein that is expressed in a variety of tissues, including the brain, spleen, and blood cells. It is characterized by a long extracellular domain that is involved in cell signaling and is composed of multiple domains, including a transmembrane region, a cytoplasmic region, and an intracellular region. The cytoplasmic region of TTLL12 contains a unique glycosylation pattern that is characterized by the presence of several specific glycans, including a N-acetyl-D-maltoside (NAD) glycosylation site.

TTLL12 is involved in a variety of cellular processes and has been implicated in the development and progression of various types of leukemia. For example, studies have shown that TTLL12 is highly expressed in human leukemia samples and that it is associated with the development of leukemia in animal models. Additionally, experiments have shown that TTLL12 is involved in the regulation of cellular processes that are critical for the development and progression of leukemia, such as cell proliferation, apoptosis, and immune surveillance.

TTLL12 has also been identified as a potential drug target for the treatment of leukemia and other diseases. The NAD glycosylation site on TTLL12 has been shown to be a potential target for small molecules and other therapeutic agents that can modulate the activity of this protein. For example, studies have shown that NAD glycosylation site on TTLL12 can be targeted by small molecules such as inhibitors of the enzyme autophosphorylation, which is a critical regulatory process that is involved in the function of many cellular processes. Additionally, The NAD glycosylation site on TTLL12 can be targeted by antibodies that can specifically recognize and block the activity of this protein.

In conclusion, TTLL12 is a protein that is expressed in various tissues and cells in the human body and is involved in the development and progression of various types of leukemia. It has also been identified as a potential drug target (or biomarker) for the treatment of leukemia and other diseases due to its unique N-acetyl-D-maltoside (NAD) glycosylation site and its involvement in the regulation of cellular processes that are critical for the development and progression of leukemia. Further research is needed to fully Understand the role of TTLL12 as a drug target and to develop effective treatments for leukemia and other diseases.

Protein Name: Tubulin Tyrosine Ligase Like 12

Functions: Negatively regulates post-translational modifications of tubulin, including detyrosination of the C-terminus and polyglutamylation of glutamate residues (PubMed:20162578, PubMed:23251473). Also, indirectly promotes histone H4 trimethylation at 'Lys-20' (H4K20me3) (PubMed:23251473). Probably by controlling tubulin and/or histone H4 post-translational modifications, plays a role in mitosis and in maintaining chromosome number stability (PubMed:20162578, PubMed:23251473). During RNA virus-mediated infection, acts as a negative regulator of the RIG-I pathway by preventing MAVS binding to TBK1 and IKBKE (PubMed:28011935)

The "TTLL12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTLL12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets